冠心病患者单核细胞中肺炎衣原体检测的价值

The measure of chlamydia pneumoniae in the peripheral blood mononuclear cell of coronary heart disease

目的探讨冠心病患者外周血单核细胞(PBMC)中肺炎衣原体(Cpn)检测的方法与临床应用价值。方法使用低渗溶血法制备PBMC,巢式聚合酶链反应(nPCR)法测定Cpn-DNA,直接免疫荧光(DIF)检测Cpn包涵体,测定150例冠心病(冠心病组)及55例非冠心病(对照组)患者。结果Cpn-DNA两组阳性率分别为32·7%(49/150)、1.8%(1/55),包涵体两组阳性率分别为13.3%(20/150)、1.8%(1/55),冠心病组与对照组比较DNA检测及包涵体阳性率明显增高。结论外周血单核细胞中可检出肺炎衣原体的病原体,包涵体与DNA检测两者间具有一致性。

Objective To determine chlamydia pneumoniae（Cpn） DNA and inclusion bodies in peripheral blood mononuclear cell（PBMC） of coronary heart disease. Methods. The PBMC were isolated by low permeate hemolysis method. The presence of Cpn-DNA and inclusion bodies were determined by nest-PCR and directed immunofluorescence（DIF） in 150 cases with CHD and 55 non CHD（control group,CG）. Results Cpn DNA positive rates were 32.7 % （49/150） in CHD and 1.8 % （ 1/55 ） in CG, simultaneity inclusion bodies were detected 13.3 % （20/150） in CHD and 1.8 % （1/55） in CG. The positivity rates of Cpn-DNA and inclusion bodies in CHD groups were significantly higher than those in control group. Conclusion Chlamydia pneumoniae DNA and inclusion bodies are present in PBMC among the significant proportion of CHD patients. PBMC sample can be collected easily and trustworthily.